arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IONIS PHARMACEUTICALS INC

IONS
$38.77 ▼ -1.34 (-3.35%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

IONIS PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.4B
Dividend Yield —
Revenue Growth -40.7% ↘
Op. Margin -38.2% ↗
ROIC -23.5% →
FCF / Share $3.32 ↗
Trailing P/E —
Price / Book 14.6x
FCF Yield 8.6%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$267.95M
↓ -40.7% —
Net Income Profit after all expenses
$-114.65M
↓ -23.9% —
Operating Margin Operating profit as % of sales
-38.2%
↑ +20.0% 6th
FCF / Share Free cash flow per share
$3.32
↑ +167.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
6
Returns ↓
11
Financial Health →
15
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 72 quarters